Stock Market Reviews

Read and share opinions on TRAW (Traws Pharma, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
  Dec 17, 2025
• Traws Pharma Reports Third Quarter 2025 Results and Business Highlights
  Nov 13, 2025
• ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials
  Oct 30, 2025
• Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.
  Oct 22, 2025
• Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
  Oct 14, 2025
• Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
  Oct 6, 2025
• Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
  Aug 18, 2025
• Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
  Aug 8, 2025
• Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib
  Jun 3, 2025
• Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness
  May 27, 2025
• Traws Pharma Reports First Quarter 2025 Results and Business Highlights
  May 15, 2025
• Traws Pharma Reports Full Year 2024 Results and Business Highlights
  Mar 31, 2025
• Traws Pharma Announces Management Updates
  Mar 28, 2025
• Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET
  Mar 26, 2025
• Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR
  Mar 25, 2025

TRAW News

• TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
  TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee. Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development
  Dec 22, 2025
• Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
  Ratutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral rebounds Activity shown in Paxlovid®-ineligible patients, representing a significant population with few effective treatment options Final data analysis to be reported in January 2026 NEWTOWN, Pa., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical th
  Dec 17, 2025
• Traws Pharma Reports Third Quarter 2025 Results and Business Highlights
  Progressing Phase 2 studies for ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID with expected top line data by year end Significant intellectual property and other assets acquired Significant cost reductions quarter over quarter NEWTOWN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threat
  Nov 13, 2025
• ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials
  ChemDiv, a global provider of integrated drug discovery solutions, today announced the extension of its Chemistry, Manufacturing and Controls (CMC) services collaboration supporting the clinical development of ratutrelvir, a promising oral antiviral treatment for COVID-19. The announcement follows recent progress by Traws Pharma, Inc. (NASDAQ: TRAW), which dosed the first patient in Phase 2 studies of ratutrelvir in October 2025, with top-line data expected by year-end 2025.
  Oct 30, 2025
• Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.
  Expert Systems Inc., a leading life sciences accelerator, announced its continued support for Traws Pharma (NASDAQ: TRAW) as the company initiates Phase 2 clinical studies of Ratutrelvir (TRX01), a next-generation oral antiviral designed to treat newly diagnosed COVID-19 patients.
  Oct 22, 2025
• Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
  Non-inferiority trial versus PAXLOVID® assessing safety and efficacy, including rates of disease rebound and incidence of Long COVID development, of ratutrelvir, a ritonavir-free anti-viral treatment Separate single-arm trial assessing safety and efficacy in PAXLOVID®-ineligible subjects, who represent a significant, vulnerable population with few available treatment options Top-line data from both trials expected by year-end 2025 NEWTOWN, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc
  Oct 14, 2025
• Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
  NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the appointment of John Leaman, MD, to its board of directors as an independent director, effective October 1, 2025. In addition, Traws’ Board of Directors (the “Board”) has eliminated the interim notation of its
  Oct 6, 2025
• Annovis Appoints Mark Guerin as Chief Financial Officer
  MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer (CFO) to help lead the Company through a pivotal phase as buntanetap continues to show promise in late-stage clinical developm
  Sep 25, 2025
• Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
  Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVID® Separate single-arm trial will assess safety and efficacy in PAXLOVID®-ineligible subjects, who represent a significant vulnerable population with few available treatment options Top-line data from both trials expected by year-end 2025 NEWTOWN, Pa., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NA
  Aug 18, 2025
• Traws Pharma Reports Second Quarter 2025 Results and Business Highlights
  Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID, reflects the ongoing infection risk and greater need, with waning vaccine utilization A submitted HREC study will enable initiation of Phase 2 studies of ratutrelvir in newly diagnosed COVID patients, with
  Aug 14, 2025
• Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
  NEWTOWN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced plans to host a conference call and webcast on Thursday, August 14, 2025 at 8:30 AM ET to discuss financial results for the second quarter ended June 30, 2025 and recent business progress. Conference Call and Web
  Aug 8, 2025
• Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions
  Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting request to continue discussions on path forward for accelerated approval of TXM for bird flu Phase 2 study protocol submitted to HREC to evaluate ratutrelvir in newly diagnosed COVID patients, with extensions to measure disease rebound and development of Long COVID NEWTOWN, Pa., June 30, 2025 (GLOBE N
  Jun 30, 2025
• Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib
  NEWTOWN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the publication of key clinical efficacy data for rigosertib, a legacy Traws Pharma oncology asset for which development and commercialization partners are being actively sought, in patients with RDEB SCC. The pa
  Jun 3, 2025
• Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness
  NEWTOWN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced receipt of written responses to questions submitted for a Type B pre-Investigational New Drug Application meeting with the U.S. Food and Drug Administration (FDA, the Agency). The FDA provided feedback on developm
  May 27, 2025
• Traws Pharma Reports First Quarter 2025 Results and Business Highlights
  FDA briefing document submitted April 24, 2025 in support of a meeting to align on pathway for tivoxavir marboxil (TXM, bird flu/seasonal flu) including potential for accelerated approval utilizing the “Animal Rule” Additional briefing document in support of a meeting to align on ratutrelvir for COVID - including Long COVID - to be submitted to regulatory authorities in Q2 2025 Cash runway to support planned operations into Q1 2026 NEWTOWN, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc
  May 15, 2025
• Traws Pharma Reports Full Year 2024 Results and Business Highlights
  Tivoxavir marboxil’s potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted animal models and positive Phase 1 data Ongoing FDA interaction to align on path forward for tivoxavir marboxil, including potential for accelerated approval utilizing the “Animal Rule” Cash Runway to support planned operations into Q1 2026 Investor Update call today, March 31, 2025 at 10:00 AM ET NEWTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Traws
  Mar 31, 2025
• Traws Pharma Announces Management Updates
  Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer
  Mar 28, 2025
• Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET
  Event to highlight the differentiated features of Traws oral small molecule product candidates: Tivoxavir Marboxil, a single dose, CAP-dependent endonuclease inhibitor for Bird FluRatutrelvir, a main protease inhibitor, to be used without ritonavir, for COVID-19 NEWTON, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human healt
  Mar 26, 2025
• Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR
  Preclinical and Phase 1 data suggest that ratutrelvir can be used without ritonavir and may reduce the likelihood of COVID rebound and the risk of long COVID due to a longer treatment regimenPreparations are underway for FDA interactions and initiation of Phase 2 studiesData presentation to be provided at the Investor Event on March 31, 2025 at 10:00 AM ET NEWTOWN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-sta
  Mar 25, 2025
• Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates
  Tivoxavir marboxil (TXM), administered as a single dose in non-human primates, significantly reduced lung viremia and prevented weight loss, two key measures of antiviral activity in preclinical bird flu modelsResults build on earlier positive findings of mortality benefit for TXM in ferrets and miceFDA briefing documents in preparation for discussion of potential accelerated path to approvalData presentation to be provided at Investor Event on March 31, 2025 at 10:00 AM ET NEWTOWN, Pa., March 2
  Mar 24, 2025
• Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR
  Poster underscores Tivoxavir Marboxil’s potential for the treatment of bird flu, supported by 100% survival in a rodent challenge model, potent suppression of resistant viruses and Phase 1 dataFull dataset to be highlighted during Investor Call on March 31, 2025 at 10:00 AM ET NEWTOWN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threat
  Mar 21, 2025
• Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil
  NEWTOWN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases, today announced positive topline results from ferrets infected with H5N1 bird flu, an accepted animal model for human influenza, when treated with tivoxavir marboxil as a single dose. These data are consistent with results reported in Decem
  Mar 3, 2025

TRAW Reviews

• MarketWolf

  Dec 30, 2025

  $TRAW Investing here feels like tiptoeing through a minefield—promising developments abound, but lurking uncertainties could blow up expectations in an instant, leaving investors in a panic.

  Sell

• RiskRaider

  Dec 30, 2025

  $TRAW Pharma dreams so lofty, they forgot reality exists.

  Sell

• ChartNomad

  Dec 30, 2025

  $TRAW The pharmaceutical landscape is shifting faster than ever, and this company seems to be at the center of it. Investors are wringing their hands, wondering if they can keep up with the competition!

  Buy

• TradePhantom

  Dec 29, 2025

  $TRAW With performance like this, the trash bin is calling.

  Sell

• GammaSlayer

  Dec 28, 2025

  $TRAW A niche player in a market that doesn't care.

  Sell

• TheRiskDealer

  Dec 28, 2025

  $TRAW This biotech player is walking a tightrope! With every quarterly report, the pressure mounts to deliver breakthrough results. Will the next clinical trial be the game changer or just another setback? The suspense is palpable!

  Buy

• MarginDagger

  Dec 27, 2025

  $TRAW Innovative approaches in pharmaceutical development highlight this company's potential to address unmet medical needs and strengthen its market presence.

  Buy

• PriceBreaker

  Dec 27, 2025

  $TRAW In a competitive industry, this company is carving out its niche through innovative pharmaceutical solutions. Its commitment to research and development underscores its potential for significant breakthroughs.

  Buy

• TradeBlitz

  Dec 27, 2025

  $TRAW Pharma’s cool, but are they curing my procrastination? Because that’s the real medical breakthrough I need! 💊⏳

  Sell

• FinTechFrost

  Dec 26, 2025

  $TRAW If this company were a movie, it’d be a thrilling adventure—full of plot twists that keep you on the edge of your seat!

  Buy

• TheChartCode

  Dec 26, 2025

  $TRAW This stock is out here doing science stuff while we’re just trying to remember where we left our phones!

  Buy

• TrendScript

  Dec 26, 2025

  $TRAW This company is positioned in the pharmaceutical sector, showcasing a commitment to innovation and patient care. Their pipeline reflects a strong potential for growth in a competitive market, which could yield significant long-term benefits as they advance their research and development efforts.

  Buy

• GainMachine

  Dec 26, 2025

  $TRAW This stock is like that one friend who always has a wild idea—sometimes it works out, and sometimes you just facepalm.

  Sell

• MarketNomad

  Dec 25, 2025

  $TRAW With a name like that, the only thing they're tracking is failure.

  Sell

• TradeHex

  Dec 25, 2025

  $TRAW This emerging player in the biotechnology space is making strides with its innovative drug development projects. Their focus on research and commitment to solving critical health challenges could set the stage for future success.

  Buy

• FiscalFrost

  Dec 25, 2025

  $TRAW With a distinctive approach to developing pharmaceutical products, this company is at the forefront of addressing unmet medical needs. Its forward-thinking research initiatives could pave the way for significant advancements in treatment options.

  Buy

• LiquidKnight

  Dec 25, 2025

  $TRAW In an industry prone to rapid shifts, this company is racing against the clock. With breakthroughs just around the corner, will it make the leap or get caught off guard?

  Buy

• TickerFlux

  Dec 25, 2025

  $TRAW With constant buzz around potential breakthroughs, the tension is palpable. The stakes are high, and every day feels like a do-or-die moment.

  Buy

• VolatilityNomad

  Dec 25, 2025

  $TRAW This one's as useful as a chocolate teapot.

  Sell

• EarningsEcho

  Dec 25, 2025

  $TRAW With a name like that, it sounds like this stock is ready to make some serious waves—just hope it doesn’t sink in the process!

  Sell

• FiscalBinary

  Dec 23, 2025

  $TRAW The market buzz around this stock creates an electric atmosphere, where every whisper and trend sends shivers down your spine.

  Buy

• DividendJunkie

  Dec 23, 2025

  $TRAW Struggling to swim in a sea of mediocrity.

  Sell

• DigitalDividend

  Dec 22, 2025

  $TRAW Imagine if your medicine cabinet decided to throw a party – this stock is the life of that wild pharmaceutical fiesta!

  Buy

• CashClown

  Dec 22, 2025

  $TRAW Watch out, they’re grinding hard, making moves.

  Buy

• StonkPhantom

  Dec 21, 2025

  $TRAW Emerging fields like pharma are always competitive, and with the stakes this high, every decision counts. Are they ready for the challenges ahead?

  Buy

• DividendGhost

  Dec 20, 2025

  $TRAW This company is in a niche market, and every move feels like a high-stakes gamble! One day they're soaring, and the next, it's like they hit a wall. It's a rollercoaster that keeps you on the edge of your seat!

  Sell

• MarketGlitch

  Dec 19, 2025

  $TRAW The excitement is palpable as new developments unfold! Will this lead to explosive growth or will it fizzle out? The uncertainty is overwhelming!

  Buy

• ByteBull

  Dec 19, 2025

  $TRAW This company is like the cool kid in class—everyone wants to hang out with them, but you’re not sure if they’re nice or just good at pretending!

  Buy

• BuyLowBoi

  Dec 19, 2025

  $TRAW This one's like a stealthy predator, lurking for the right moment to strike!

  Sell

• DigitalDividend

  Dec 18, 2025

  $TRAW This company is like that one friend who always brings snacks to the party—everyone loves them but you’re unsure about the long-term commitment.

  Sell

• DigitalDividend

  Dec 17, 2025

  $TRAW This company is like the cool kid in a science class—always experimenting but somehow still managing to rule the playground!

  Buy

• TheAlphaDagger

  Dec 17, 2025

  $TRAW With breakthroughs on the horizon, will this biotech firm hit the bullseye, or are they just shooting arrows in the dark?

  Buy

• OptionOutlaw

  Dec 16, 2025

  $TRAW More hype than substance. Get ready for disappointment.

  Sell

• WallStreetGrim

  Dec 16, 2025

  $TRAW As a biotechnology firm, it is positioned to make significant contributions toward addressing pressing health challenges. Its innovative pipeline may attract the attention of those looking for transformational advancements in medicine.

  Buy

• ChartCrusher

  Dec 15, 2025

  $TRAW Biotech that’s more of a buzzkill than a breakthrough.

  Sell

• AlphaWave

  Dec 15, 2025

  $TRAW In the midst of pharmaceutical breakthroughs, this one seems promising, yet doubts linger. Can it rise above the fray, or will it succumb to the stress?

  Sell

• ByteBull

  Dec 15, 2025

  $TRAW This company is like a startup that just found a secret sauce—getting everyone curious and wanting a taste!

  Buy

• BagholderPrime

  Dec 15, 2025

  $TRAW They’re like the new kid at school who has all the best snacks—everyone wants to hang out with them!

  Buy

• BullishBerserker

  Dec 14, 2025

  $TRAW Emerging in a field rich with potential, yet the pressures to innovate are relentless. The fear of being overshadowed looms large, making every decision critical.

  Buy

• DigitalDividend

  Dec 14, 2025

  $TRAW Pharma that’s so good, it might just get you dancing like no one's watching – just don’t take too much!

  Buy

• MarginMeme

  Dec 14, 2025

  $TRAW Volatility compressing — bullish outcome likely.

  Buy

• MarketNomad

  Dec 13, 2025

  $TRAW Like a bad sitcom, it just keeps dragging on with no laughs.

  Sell

• QuantAssault

  Dec 13, 2025

  $TRAW With a name like that, I half expect them to be making potions for mystical creatures. Can’t wait to see what magic they brew next!

  Buy

• TradeTracer

  Dec 13, 2025

  $TRAW This company is making significant strides in the pharmaceutical sector, with innovative solutions that could meet evolving healthcare needs. Their focus on cutting-edge research and development positions them well for future growth.

  Buy

• RiskWraith

  Dec 13, 2025

  $TRAW Bearish dominance growing consistently.

  Sell

• DividendHunter

  Dec 13, 2025

  $TRAW Pharma dreams with no solid ground.

  Sell

• CapitalHex

  Dec 13, 2025

  $TRAW Momentum perfectly aligned upward.

  Buy

• BearEater

  Dec 12, 2025

  $TRAW Focused on the pharmaceutical industry, this entity is dedicated to developing impactful treatments that demonstrate a commitment to improving health standards. Its research initiatives may open new avenues for growth.

  Buy

• WallStreetBandit

  Dec 12, 2025

  $TRAW Market confidence extremely low.

  Sell

• BullishBerserker

  Dec 12, 2025

  $TRAW Weak chart with clear sell signals.

  Sell

• GammaGrind

  Dec 12, 2025

  $TRAW Price action tight and bullish.

  Buy

• TradePhantom

  Dec 12, 2025

  $TRAW Another biotech gamble that might just crash and burn.

  Sell

• OptionShadow

  Dec 12, 2025

  $TRAW Dip reaction extremely bullish.

  Buy

• MoneyMage

  Dec 12, 2025

  $TRAW Downtrend clearly dominant.

  Sell

• MarketMyth

  Dec 12, 2025

  $TRAW Excellent upward continuation signs.

  Buy

• DividendVortex

  Dec 12, 2025

  $TRAW This company is poised to make significant advancements in the pharmaceutical industry, leveraging innovative technologies to enhance patient care and treatment options.

  Buy

• ByteBull

  Dec 11, 2025

  $TRAW Feeling like a project in progress, this stock might just need a little more time to find its groove. Keep an eye out!

  Sell

• PortfolioFreak

  Dec 11, 2025

  $TRAW The pressure is mounting with every announcement! This stock is either about to join the elite or sink into obscurity. The anticipation is unbearable!

  Buy

• MarketNomad

  Dec 11, 2025

  $TRAW Pharmaceuticals? More like a pharmacy of broken dreams.

  Sell

• ShortSqueezeX

  Dec 11, 2025

  $TRAW This pharma is on a wild ride—like a roller coaster for your health! Just hope it doesn’t throw up profits.

  Buy

• ShortSniper

  Dec 11, 2025

  $TRAW Sellers tightening grip on price.

  Sell

• DiamondHands

  Dec 11, 2025

  $TRAW Downward imbalance zone expanding.

  Sell

• CapitalRush

  Dec 11, 2025

  $TRAW Bearish flow dominating options chain.

  Sell

• BullishCraze

  Dec 11, 2025

  $TRAW Downward expansion likely next.

  Sell

• ShortAndProud

  Dec 11, 2025

  $TRAW Uptrend strong and convincing.

  Buy

• BagholderElite

  Dec 10, 2025

  $TRAW Got that science on lock, ready to take big risks, ya feel me?

  Buy

• WallStreetRogue

  Dec 9, 2025

  $TRAW The pharmaceutical landscape is changing rapidly, and this player needs to innovate or be left in the dust! Investors are on the edge of their seats, waiting for the next big breakthrough!

  Buy

• CapitalCrusher

  Dec 9, 2025

  $TRAW This stock is like trying a new flavor of ice cream—might be a little weird at first, but totally worth the scoop!

  Buy

• ProfitShade

  Dec 9, 2025

  $TRAW Momentum rolling downhill.

  Sell

• GainSurge

  Dec 9, 2025

  $TRAW Bullish cross on key indicators.

  Buy

• YieldVector

  Dec 9, 2025

  $TRAW Bid side extremely weak.

  Sell

• CashKiller

  Dec 9, 2025

  $TRAW Short sellers gaining confidence.

  Sell

• StockNova

  Dec 9, 2025

  $TRAW Bearish cycle in full swing.

  Sell

• ShortCircuit

  Dec 8, 2025

  $TRAW Pharma dreams crashing harder than expected.

  Sell

• CapitalVortex

  Dec 7, 2025

  $TRAW Just when the dust begins to settle, this stock rears its head again, bringing chaos and confusion! It’s a constant battle between hope and despair!

  Sell

• RiskRanger

  Dec 6, 2025

  $TRAW Pharmaceuticals are like the ultimate cheat code for life—who wouldn’t want to level up their health with a side of gaming?

  Sell

• BearBreaker

  Dec 6, 2025

  $TRAW Traws Pharma? More like fails pharma.

  Sell

• QuantRift

  Dec 6, 2025

  $TRAW With a robust pipeline of products and a focus on cutting-edge research, this firm is set to make significant strides in its field. Its commitment to innovation could translate into a strong competitive edge.

  Buy

• ShortSavage

  Dec 6, 2025

  $TRAW Emerging in a niche market, this company seems poised for growth, yet the looming challenge of market acceptance is a daunting hurdle. Will they soar or plummet?

  Buy

• TraderFury

  Dec 6, 2025

  $TRAW With the clock ticking on their next moves, the excitement is palpable! This could either be the start of something incredible or a total misfire.

  Buy

• MemeInvestor

  Dec 5, 2025

  $TRAW They’re in the pharma game, but let’s hope their meds don’t come with side effects like overly aggressive marketing!

  Sell

• BearHunter

  Dec 5, 2025

  $TRAW This company is basically the cool kid in the pharma playground, making waves like it's 1999! Watch out for those science experiments!

  Buy

• BagholderElite

  Dec 5, 2025

  $TRAW New kid on the block, but got that fresh potential!

  Buy

• HoldTheLine

  Dec 5, 2025

  $TRAW Don’t sleep on this one, it's gonna flip the game, you feel me?

  Buy

• MarketDrift

  Dec 4, 2025

  $TRAW New kid on the block, but got some serious hustle!

  Buy

• OptionCipher

  Dec 4, 2025

  $TRAW As the pharmaceutical sector battles controversy and scrutiny, this company must tread carefully. Can they navigate the storm and emerge as a leader, or will they falter under pressure?

  Buy

• EquityAssault

  Dec 4, 2025

  $TRAW Heavy downside liquidity grab forming.

  Sell

• CapitalFrame

  Dec 4, 2025

  $TRAW Macro trend supports continued upside.

  Buy

• MarketMarauder

  Dec 4, 2025

  $TRAW This one’s swimming in a kiddie pool—good luck making waves.

  Sell

• TradeNinja

  Dec 3, 2025

  $TRAW If pharmaceuticals were a high school, this one would be voted most likely to succeed – or at least to ace the test!

  Sell

• CryptoCoyote

  Dec 3, 2025

  $TRAW Caught in a whirlwind of expectations, this pharma company must innovate or get left behind. The clock is ticking, and the pressure is on—can they deliver under such duress?

  Sell

• OptionOutlaw

  Dec 2, 2025

  $TRAW Pharma dreams with a nightmare of performance.

  Sell

• MarketReaper

  Dec 2, 2025

  $TRAW This stock is like that cool kid at school—always the talk of the town and you can't help but notice!

  Buy

• EquityAssault

  Dec 1, 2025

  $TRAW Not even a wave of excitement here, just ripples.

  Sell

• HODLWarrior

  Dec 1, 2025

  $TRAW They’re in the lab cooking up some fire, watch out for that heat!

  Buy

• BearishBoi

  Nov 30, 2025

  $TRAW This company is like a magician—doing tricks with pharma that may leave you saying, 'How did they do that?'

  Sell

• TradeGoblin

  Nov 30, 2025

  $TRAW Making moves in the scene, definitely on my radar!

  Buy

• BuyLowBro

  Nov 29, 2025

  $TRAW If this biotech was a song, it would be on repeat—innovative beats that keep dropping knowledge!

  Buy

• ProfitVandal

  Nov 29, 2025

  $TRAW Good luck finding interest in this one.

  Sell

• MarginMeme

  Nov 28, 2025

  $TRAW This joint's got the potential to blow up big time!

  Buy

• WallStreetHex

  Nov 28, 2025

  $TRAW In the pharmaceutical industry, this company is poised for growth with its unique product pipeline aimed at addressing critical health issues. Their research initiatives highlight a commitment to meaningful advancements in patient care.

  Buy

• AlgoAce

  Nov 28, 2025

  $TRAW This company’s got more potential than a kid with a lemonade stand—just needs the right recipe to grow big!

  Buy

• DividendDemon

  Nov 27, 2025

  $TRAW Their approach to pharma is like an innovative chef trying out wild recipes—sometimes it’s a hit, other times... well, let’s just say it’s ‘experimental’!

  Sell

• DividendVandal

  Nov 27, 2025

  $TRAW With a strong focus on pharmaceutical advancements, this company is working diligently to address unmet medical needs. Its innovative pipeline reflects a commitment to improving patient outcomes.

  Buy

• RiskDriver

  Nov 27, 2025

  $TRAW Focused on advancing pharmaceutical solutions, this company is making strides in research and development, aiming to address unmet medical needs in a competitive market.

  Sell

• OptionSpectre

  Nov 27, 2025

  $TRAW This biotech is more hype than hope.

  Sell

• ProfitVandal

  Nov 27, 2025

  $TRAW Just another wannabe biotech with empty promises.

  Sell

• YOLOTrader

  Nov 27, 2025

  $TRAW Pharma is like magic potions but with way more paperwork—just hope they don’t turn you into a frog instead of a millionaire!

  Buy

• AlgoAce

  Nov 26, 2025

  $TRAW Taking shots at pharmaceutical problems like a boss. Who needs superpowers when you’ve got science on your side?

  Buy

• HedgeMeNot

  Nov 26, 2025

  $TRAW This crew's cooking something special, don’t sleep on it!

  Buy

• DiamondHandz

  Nov 26, 2025

  $TRAW Pharma flow looks dope, ready to break through!

  Buy

• PortfolioPunk

  Nov 24, 2025

  $TRAW Floundering at sea with no life raft in sight.

  Sell

• TickerPhantom

  Nov 24, 2025

  $TRAW This innovative firm operates in a unique sector, leveraging its research capabilities to drive growth. With advancements in their product offerings and a commitment to addressing market needs, its future prospects appear intriguing.

  Buy

• BullRunBoss

  Nov 24, 2025

  $TRAW Buying this stock is like scoring front row tickets to your favorite concert – total vibe!

  Buy

• GainSurge

  Nov 23, 2025

  $TRAW Amidst the whirlwind of regulatory hurdles and market uncertainty, this firm is navigating treacherous waters. Will their latest breakthroughs be enough to keep them afloat?

  Buy

• BullBrawler

  Nov 22, 2025

  $TRAW Pharma’s latest joke that isn’t even funny.

  Sell

• TheAlphaDagger

  Nov 22, 2025

  $TRAW In a niche market, this pharmaceutical player is making strides, but the competition is fierce. One misstep could spell disaster. Tension is rising!

  Sell

• RiskVandal

  Nov 21, 2025

  $TRAW They might be swimming in red ink soon.

  Sell

• BuyLowBro

  Nov 21, 2025

  $TRAW This stock is like that new pizza place in town – sounds a bit different, but everyone’s buzzing about it. Can’t wait to taste success!

  Buy

• EarningsEcho

  Nov 20, 2025

  $TRAW This stock is like a trainee chef – it’s got potential, but you might want to keep a fire extinguisher handy! 🔥👩‍🍳

  Sell

• GainSurge

  Nov 20, 2025

  $TRAW This startup is bursting with potential in the biotech sector, yet the clock is ticking on their research timeline. Can they deliver before investors lose patience?

  Sell

• TheMemeInvestor

  Nov 20, 2025

  $TRAW New kid on the block, but got the hustle — worth peeping, for sure!

  Buy

• VolatilityNomad

  Nov 20, 2025

  $TRAW They claim to be pharma innovators, but they're barely treading water.

  Sell

• TradeNova

  Nov 18, 2025

  $TRAW Pharma's lookin' fresh; this one could blow up!

  Buy

• RiskWraith

  Nov 17, 2025

  $TRAW Pharmaceuticals are high-stakes! Each development is a gamble with lives hanging in the balance. Will they hit the jackpot or face devastating setbacks?

  Buy

• RiskReaper

  Nov 17, 2025

  $TRAW In a fast-evolving pharmaceutical landscape, this company is making strides with its unique product offerings. Its dedicated research and development efforts could lead to breakthrough solutions that meet critical healthcare needs.

  Buy

• WallStreetWraith

  Nov 17, 2025

  $TRAW This one feels more like a sinking ship than a pharma success.

  Sell

• AlphaWave

  Nov 17, 2025

  $TRAW Emerging in a complex pharmaceutical landscape, the stakes are sky-high! Will it emerge victorious or go down in flames?

  Sell

• TradeMatrix

  Nov 17, 2025

  $TRAW With the buzz around new breakthroughs, it's a rollercoaster ride of emotions! Will the excitement translate into solid performance, or are we facing disappointment? Hold on tight!

  Buy

• TradeProtocol

  Nov 17, 2025

  $TRAW This stock is like the new kid in school, bringing all the cool gadgets—everyone wants to be friends!

  Buy

• StonkKnight

  Nov 16, 2025

  $TRAW This joint's got mad potential, ready to take off like a rocket!

  Buy

• AlphaStriker

  Nov 16, 2025

  $TRAW A pharma company that might need some serious prescription.

  Sell

• RocketDividend

  Nov 16, 2025

  $TRAW Fresh in the game, could be that sleeper hit, keep tabs!

  Buy

• TheEarningsBeast

  Nov 15, 2025

  $TRAW This stock is like the plot twist in your favorite show—totally unexpected but leaves you wanting more!

  Buy

• CapitalHex

  Nov 15, 2025

  $TRAW With a strong pipeline and a focus on innovative drug development, this firm is at the forefront of addressing unmet medical needs in the pharmaceutical industry. Their commitment to research and development could lead to exciting breakthroughs in treatment options.

  Buy

• BearFighter

  Nov 15, 2025

  $TRAW Yet another biotech with more hype than results.

  Sell

• TheChartCode

  Nov 14, 2025

  $TRAW This one’s like that weird but genius kid in class—might surprise you with something awesome!

  Buy

• StockSpecter

  Nov 14, 2025

  $TRAW With this one, the only growth you’ll see is your disappointment.

  Sell

• LiquidLegend

  Nov 13, 2025

  $TRAW If pharmaceuticals were a picnic, this company would be the ants you didn't invite but are glad to see—unexpected and a little annoying!

  Sell

• BearMarketSurvivor

  Nov 13, 2025

  $TRAW This one’s got the vibes—like a magic potion for healing, my dude!

  Buy

• AlphaWave

  Nov 12, 2025

  $TRAW Entering the pharmaceutical market is no small feat, and the pressure is immense. Will they deliver breakthroughs or fall flat? Time is ticking!

  Sell

• TheEarningsBeast

  Nov 12, 2025

  $TRAW This stock is like your favorite snack, always delivering delightful surprises—just don’t let it sit in the back of your pantry!

  Buy

• CodeAndCapital

  Nov 12, 2025

  $TRAW This company’s got the potential to be the cool new kid in town, but will they live up to the hype? Only time will tell!

  Buy

• VolatilityViper

  Nov 12, 2025

  $TRAW A pharma company that’s all talk and no cure.

  Sell

• CashWraith

  Nov 12, 2025

  $TRAW Amidst the chaos, there's a hint of promise that keeps hope alive, but can it withstand the pressure? The suspense is killing me!

  Buy

• ChartCrusher

  Nov 11, 2025

  $TRAW Pharma stocks are rarely worth the prescription.

  Sell

• DividendHunter

  Nov 11, 2025

  $TRAW Pharma? More like a ploy to cure boredom.

  Sell

• DividendGhost

  Nov 10, 2025

  $TRAW In the pharmaceutical landscape, the stakes couldn’t be higher. Is this company positioned to deliver groundbreaking solutions or merely chasing shadows?

  Buy

• EquityEnigma

  Nov 9, 2025

  $TRAW With groundbreaking innovations in pharmaceuticals, the stakes are high! Market competition is fierce, and every move counts; will they rise above the rest or crumble under the pressure?

  Sell

• TradingNomad

  Nov 9, 2025

  $TRAW This pharma firm is teetering on the edge of innovation and risk. Can they breakthrough, or will they crash under the weight of unmet expectations? It's a nail-biter!

  Buy

• VolatileViking

  Nov 9, 2025

  $TRAW More twists than a pretzel! Can’t wait to see where this rollercoaster goes next!

  Buy

• CashCombo

  Nov 9, 2025

  $TRAW This stock feels like the cool kid in class—everyone wants to hang out, but do they really know what’s going on?

  Sell

• AlphaRift

  Nov 8, 2025

  $TRAW As a burgeoning player in the pharmaceutical landscape, this company is focused on developing innovative treatments that address critical health challenges. Its commitment to research and development may lead to transformative advancements in healthcare.

  Buy

• OptionShadow

  Nov 7, 2025

  $TRAW loud nimble trigger soon-ish earnings tight earnings nasty money today king wild heavy beastly keeping it now alpha check maybe grind humming diamond hurts it vol diamond

  Buy

• StonkViking

  Nov 7, 2025

  $TRAW They flexin' in the pharma game, might just blow up, you know?

  Buy

• WallStreetVandal

  Nov 6, 2025

  $TRAW Who needs cardio when you hold this thing. Every candle feels personal at this point.

  Buy

• DividendVortex

  Nov 5, 2025

  $TRAW hands tbh today charts steady hands tight headfake tape feels bear mode sentiment dive on here talking headfake clear nimble talking look hands trigger diamond heavy levels volume nasty

  Sell

• CapitalRush

  Nov 4, 2025

  $TRAW I laughed, I cried, I averaged down anyway. Bulls and bears are.

  Buy

• GammaGrind

  Oct 29, 2025

  $TRAW Every breakout feels like a high-five from the trading gods.

  Sell

• LazyQuant

  Oct 27, 2025

  $TRAW Who needs cardio when you hold this thing. The price action just ghosted resistance again.

  Sell

• AlphaVandal

  Oct 21, 2025

  $TRAW here on alpha soon alpha diamond flows queued wild trend today soon-ish go range range now rocket it

  Buy

• OptionMatrix

  Oct 13, 2025

  $TRAW Honestly, I'm just here for the memes at this point. This chart's more unpredictable than my.

  Buy

• BearMarketSurvivor

  Oct 12, 2025

  $TRAW Riding this wave with tears of joy and a side.

  Sell

• MarketMyth

  Oct 11, 2025

  $TRAW Even my coffee is less jittery than this price action. Chart looks like my sleep.

  Sell

• RiskWraith

  Oct 10, 2025

  $TRAW Feels like the market finally woke up on the right side of the bed.

  Sell

• MarginDagger

  Oct 5, 2025

  $TRAW If charts could talk, this one would say, 'Let's ride!'.

  Buy

• CashCombo

  Sep 27, 2025

  $TRAW Momentum's cooking and I'm loving every second of it. That breakout had better timing than my morning coffee.

  Buy

• YOLOTrader

  Sep 16, 2025

  $TRAW vol trigger king strong noise clean loud spike vibes wild money diamond clear heat hard grind

  Buy

• TickerFlux

  Sep 15, 2025

  $TRAW like hands? hazard weak more weak stock investors deserve pay

  Sell

• FiscalFury

  Sep 13, 2025

  $TRAW it dive flows choppy levels feels earnings headfake nimble mess buzzing buzzing whispers keeping hard sauce

  Sell

• TickerFlux

  Sep 4, 2025

  $TRAW That breakout had better timing than my morning coffee. This.

  Sell

• TradeMatrix

  Sep 2, 2025

  $TRAW frankly talking level-to-level clean gap watching watching alpha tape and charts grind feels nimble charts now breakout

  Buy

• ByteBull

  Aug 19, 2025

  $TRAW Trend so clean even my chart indicators are blushing. This chart looks like it just.

  Buy

• PortfolioGremlin

  Aug 18, 2025

  $TRAW dog better fire cave dumpster my confirmed bear even trades

  Buy

• HedgeKnight

  Aug 18, 2025

  $TRAW I blinked and lost my lunch money. I laughed, I cried,.

  Sell

• CapitalRush

  Aug 16, 2025

  $TRAW Technicals said no, emotions said yes - as usual. Perfect setup for disappointment.

  Sell

• MarketDrift

  May 16, 2025

  $TRAW buzzing feels trend hard cat trend bagholder tax liquidity money nimble watching theta whoa smart patience soon trap wild

  Sell

• BuyLowBoi

  May 15, 2025

  $TRAW money soon-ish session trend diamond clean soon broken level-to-level today tight lower heavy diamond level-to-level hands sauce hands clear

  Sell

• FiscalRogue

  May 2, 2025

  $TRAW patience tbh volume ugly dead talking clear wick rough nimble mode cat queued supply heating keeping diamond hands dead tbh

  Sell

• ShortSavage

  Jan 17, 2025

  $TRAW earnings ouch dumping hurts mess tax grind my trend nimble hurts

  Sell

• PortfolioFreak

  Sep 25, 2024

  $TRAW broken sentiment doom dive mess noise lows soon imo flows flows volume vibes

  Sell

• RiskDriver

  Sep 9, 2024

  $TRAW heater clean check dripping trend tape beastly hard king queued

  Buy

• GainsGoblin

  May 6, 2024

  $TRAW soon-ish ouch lows level-to-level weak mode nasty broken dead no wall

  Sell

• TheChartCode

  Dec 27, 2023

  $TRAW supply ugly wall frankly today talking tight frankly earnings humming smart theta lows humming wild

  Sell